Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (431-440 of 523) with videos related to

Pageof 53
Sort By:
Dermatology and Therapy|January 21, 2021
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis RegistryAlice B Gottlieb, Joseph F Merola, Joshua Cirulli, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Clinical and Experimental Dermatology|May 24, 2025
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasisMark Lebwohl, Melinda J Gooderham, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Archives of Dermatology|December 17, 2003
A randomized trial of etanercept as monotherapy for psoriasisAlice B Gottlieb, Robert T Matheson, Nicholas Lowe, et al.
The Journal of Dermatological Treatment|March 7, 2012
Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasisShiu-Chung Au, Ari M Goldminz, Noori Kim, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
The British Journal of Dermatology|April 15, 2018
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi processL Thorlacius, J R Ingram, B Villumsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasisEiko Toichi, Gisela Torres, Thomas S McCormick, et al.
Journal of the American Academy of Dermatology|December 21, 2024
The association between obesity and efficacy of psoriasis therapies: An expert consensus panelJoshua Burshtein, April Armstrong, May Chow, et al.
Pageof 53

Showing results (431-440 of 523) with videos related to

Sort By:
Pageof 53
Dermatology and Therapy|January 21, 2021
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis RegistryAlice B Gottlieb, Joseph F Merola, Joshua Cirulli, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Clinical and Experimental Dermatology|May 24, 2025
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasisMark Lebwohl, Melinda J Gooderham, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Archives of Dermatology|December 17, 2003
A randomized trial of etanercept as monotherapy for psoriasisAlice B Gottlieb, Robert T Matheson, Nicholas Lowe, et al.
The Journal of Dermatological Treatment|March 7, 2012
Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasisShiu-Chung Au, Ari M Goldminz, Noori Kim, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
The British Journal of Dermatology|April 15, 2018
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi processL Thorlacius, J R Ingram, B Villumsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasisEiko Toichi, Gisela Torres, Thomas S McCormick, et al.
Journal of the American Academy of Dermatology|December 21, 2024
The association between obesity and efficacy of psoriasis therapies: An expert consensus panelJoshua Burshtein, April Armstrong, May Chow, et al.
Pageof 53